ALPS Group’s vision goes beyond NASDAQ — it’s about shaping the future of ethical biotechnology.
As featured in World Journal, ALPS continues to advance gene sequencing, AI-driven diagnostics, and regenerative therapy platforms designed to make next-generation medical solutions affordable and accessible.
Founded by Dr. Tham Seng Kong, ALPS stands at the forefront of Southeast Asia’s biotech revolution — building bridges between research, real-world impact, and human-centered innovation.
Current initiatives include developing personalized mRNA vaccines, expanding into Indonesia and the Middle East, and driving collaboration between biotech, healthcare, and technology ecosystems.
“We left behind comfort to ensure science serves humanity, not just the privileged few.”
🔗 Read the full article: World Journal
